Enhabit (NYSE:EHAB) Issues FY 2025 Earnings Guidance

Enhabit (NYSE:EHAB) issued an update on its FY 2025 earnings guidance on Wednesday morning. The company provided EPS guidance of 0.410-0.510 for the period, compared to the consensus EPS estimate of 0.290. The company issued revenue guidance of $1.1 billion-$1.1 billion, compared to the consensus revenue estimate of $1.1 billion.

Analyst Ratings Changes

A number of research firms have issued reports on EHAB. Jefferies Financial Group raised Enhabit from a “hold” rating to a “buy” rating and raised their target price for the stock from $8.25 to $9.50 in a research report on Monday, December 9th. Leerink Partners reiterated a “market perform” rating and set a $8.00 price target (down previously from $8.50) on shares of Enhabit in a research note on Tuesday, November 19th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and one has given a buy rating to the company’s stock. According to MarketBeat.com, Enhabit has a consensus rating of “Hold” and a consensus target price of $8.75.

Enhabit Stock Up 1.0 %

EHAB opened at $8.55 on Thursday. Enhabit has a 12 month low of $6.85 and a 12 month high of $11.74. The company has a market cap of $430.13 million, a PE ratio of -3.69 and a beta of 1.83. The company has a current ratio of 1.46, a quick ratio of 1.46 and a debt-to-equity ratio of 0.85. The company has a 50 day moving average of $8.18 and a 200 day moving average of $7.90.

Insider Transactions at Enhabit

In other news, Director Stuart M. Mcguigan bought 15,000 shares of the firm’s stock in a transaction that occurred on Tuesday, December 10th. The shares were acquired at an average price of $8.81 per share, with a total value of $132,150.00. Following the acquisition, the director now owns 46,810 shares of the company’s stock, valued at approximately $412,396.10. The trade was a 47.15 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Jeffrey Bolton bought 4,000 shares of the stock in a transaction on Thursday, December 12th. The stock was purchased at an average price of $8.69 per share, for a total transaction of $34,760.00. Following the completion of the purchase, the director now directly owns 98,144 shares in the company, valued at approximately $852,871.36. This represents a 4.25 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Corporate insiders own 1.90% of the company’s stock.

Enhabit Company Profile

Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.